Market Size (2016)
2016
—
Healthcare
Smart Insulin Pens Market
By Segment, By Region, And Segment Forecasts, 2016 – 2027
Vertical: HealthcareBase Year: 201911 Sections
Executive Summary
Smart Insulin Pens Market — Snapshot
Projected (2027)
2027
—
CAGR (2016–2027)
N/A
Key Players
106+
This report covers Smart Insulin Pens Market with forecasts from 2016 to 2027. 106 key companies are profiled.
Key Insight
Smart Insulin Pens Market is a key focus area for market intelligence and strategic research.
Market Performance Trend
Historical performance and future projections (2020–2030, USD Billion)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Scope & Coverage
What this report covers
- Geographic Coverage: This analysis covers 5 regions: South America, North America, Europe, Asia Pacific, Middle East and Africa.
- Market Segmentation: The market is analyzed across key segments with forecasts from 2016 to 2027.
- Competitive Landscape: 106 leading companies are profiled, covering market positioning, strategies, and recent developments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Overview
Smart Insulin Pens Market — Growth Trajectory
The evolution of technologies to manage diabetes has led to the emergence of smart insulin pens. It helps both patients and health care professionals overcome problems such as poor insulin adherence, incorrect insulin initiation, and medication errors. Smart insulin pens are used for external insulin delivery and offer an easy to carry solution to diabetes management. In recent years, the demand for insulin pens has increased owing to the rise in the incidence of diabetic patients coupled with their cost-effective nature as compared to insulin pumps. In addition, their simple functioning and accuracy-related to insulin dosing further stimulate their demand.
Market Share by Application
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Dimensions
How this market is segmented
- Product Type Product Type is broken down into: Connecting Device, Smart Pen.
- Distribution Channel Distribution Channel is broken down into: Hospital/Retail pharmacies, Online.
Geographic Analysis
Regional market breakdown
- South America South America is one of the key regions covered in this market analysis.
- North America North America is one of the key regions covered in this market analysis.
- Europe Europe is one of the key regions covered in this market analysis.
- Asia Pacific Asia Pacific is one of the key regions covered in this market analysis.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansResearch Methodology
Smart Insulin Pens Market — How We Researched This Market
This report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2019
Historical Period
2016 – 2019
Forecast Period
2019 – 2027
Primary Interviews
150+
Research Process
Historical data (2016–2019) and forecast period (2019–2027)
1
Problem Definition
- Market scoping
- Objective setting
- Framework design
2
Secondary Research
- Literature review
- Data mining
- Trend analysis
3
Primary Research
- Expert interviews
- Field visits
- Surveys
4
Data Analysis
- Quantitative modeling
- Statistical testing
- Validation
5
Insights & Reporting
- Synthesis
- Recommendations
- Visualization
Research Depth
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Competitive Landscape & Porter's Five Forces
Smart Insulin Pens Market — Competitive Analysis
Michael Porter’s five forces model gives a framework that models the global smart insulin pens market, which is influenced by five forces. The strategic business managers trying to create an edge over competing firms in the smart insulin pens market and can utilize this model to comprehend better the industry connection in which the firm operates. The components of each of the forces and the degree or impact of each component in the context of the global smart insulin pens industry have been broken down and analyzed.
BARGAINING POWER OF SUPPLIERS
The suppliers in the global smart insulin pens industry are the developers and manufacturers of smart insulin pens. There are a low number of suppliers in the global smart insulin pens market, leading to an averagely low amount of bargaining power in the market. The switching cost of these suppliers is less as suppliers tend to enter into long term associations with the smart insulin pens manufacturers. Due to the low bargaining power of suppliers, the profit potential of the global smart insulin pens industry is increasing.
BARGAINING POWER OF BUYERS
The bargaining power of smart insulin pens buyers is moderate in the global smart insulin pens market; this is because of a large number of economical insulin pens providers in the industry. There are a limited number of manufacturers or suppliers of smart insulin pens present in the industry, which makes it a medium competitive market. Hence, the availability of a low number of manufacturers expands the selection arena of the sellers for the buyers, which leads to a reduction in the bargaining power.
THREAT OF NEW ENTRANTS
The threat of new entrants is high in the global smart insulin pens market. The smart insulin pens market is also characterized by a reasonable degree of brand loyalty, where establishing a brand name is difficult for newcomers. The availability of standard insulin pens in the market would help manufacturers to adopt the technological change in the products and launch innovative products in the market. Furthermore, the cost involved in the manufacturing setup is medium, which discreetly comforts the new entrants to enter the market easily.
THREAT OF SUBSTITUTES
The threat of substitutes in the global smart insulin pens market is very moderate. The buyer’s propensity to substitute is less due to the brand loyalty of customers in this market. In addition, the availability of the standard insulin pens in the market can affect the purchasing decisions of the buyers.
INTENSITY OF RIVALRY
The degree of competition in the global smart insulin pens market is considered to be moderate. The reserved degree of product differentiation among existing players increases the intensity of rivalry in the market. Smart insulin pens manufacturing companies are trying to develop products with high quality and enhanced safety to increase the demand for these products in the developed countries and developing regions. To overcome the competition, players are engaged in developing a process to lower their manufacturing costs. Moreover, the players are also developing advanced products for differentiating their brand from their competitors.
Empower your Business
with InsightsSave over 20% on
with Insights
Save over 20% on
Annual Subscription
See plans for professionals or small and medium businesses.
Analytics
Smart Insulin Pens Market — Key Findings
Analytical insights on Smart Insulin Pens Market covering market dynamics, competitive landscape, and strategic outlook.
Key Analytical Findings
Smart Insulin Pens Market represents a significant market opportunity with multiple growth drivers across regions and segments.
Market Dynamics
The growing prevalence of diabetes globally, rising product launches and approvals, increasing geriatric population, sedentary lifestyle and unhealthy diet, and growing awareness and funding for treatment of diabetes are driving the global smart insulin pens market. However, the rising adoption of non-invasive drug delivery systems is expected to hamper the growth of this market during the forecast period. Nevertheless, untapped markets are likely to set a lucrative opportunity for the growth of this market in the near future.
Market Drivers
Smart insulin pens are primarily used for diabetes management. The Increasing prevalence of diabetes is anticipated to boost the demand for these devices in the coming years. According to the data by the Centers for Disease Control and Prevention in 2017, an estimated 30.3 million people in the US were diagnosed with diabetes. Similarly, in the UK, according to the British Diabetic Association, about 3.69 million were diagnosed with diabetes in 2016, and it reached to 3.92 million in 2019. The increasing number of diabetic patients is expected to support the growth of the market.
Moreover, in 2019, according to the International Diabetes Federation (IDF), more than 1.1 million children and adolescents were living with type 1 diabetes across the globe. Similarly, according to the research article published in the National Center for Biotechnology Information (NCBI), the diabetic population in India is estimated to reach 69.9 million by 2025 and 80 million by 2030. The increasing population of diabetes is expected to boost the growth of the market during the forecast period.
Market Opportunities
The companies into the manufacturing of drugs and devices for diabetes treatment and prevention can expand their business by licensing their diabetes treatment products or signing distributor agreements with smaller companies present in untapped markets. Russia and South Africa are untapped markets as compared to China, India, or Brazil. Also, the prevalence of diabetes is increasing in these nations. According to the data published by the International Diabetes Federation in 2017, the incidence of diabetes in South Africa and Russia was 5.4% and 7.9%, respectively. South Africa reported 1,826,100 cases, and Russia reported 8,455,300 cases of diabetes in 2017. Therefore, the rising prevalence in these untapped markets is creating immense opportunities for companies to expand their businesses.
Market Restraints
Increasing the adoption of non-invasive drug delivery devices such as the inhalation drug delivery system is likely to hamper the growth of the market during the forecast period. There are many advantages of non-invasive methods over invasive drug delivery systems that reduce the preference of invasive drug delivery systems in diabetic care management. The inhalation drug delivery system is a user-friendly technology, and aids self-administration and pain-free dosing for patients as compared to subcutaneous and intravenous methods. The MannKind Corporation (US) offers Afrezza, an inhalation drug used in the treatment of diabetes mellitus. According to a research study, the number of prescriptions of Afrezza increases by approximately 28% year on year (YoY).Hence, the increasing adoption of non-invasive drug delivery systems is expected to hamper the growth of the market during the forecast period.
Strategic Outlook and Future Directions
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Companies
Key companies profiled in Smart Insulin Pens Market
Profiles of 106 companies operating in the Smart Insulin Pens Market market, including revenue, employee count, and market positioning where available.
Showing 106 of 106 companies
Digital Me
Digital Medics Pty Ltd
Healthcare
Company Headquarters: Sydney, Australia Founded: 2006 Workforce: ~ 11-50 Company Working: Digital Medics Pty Ltd (Digital Medics) offers innovative SmartPlus Digital Insulin Pen and the Diabetes IQ App for better diabetes care and control. Digital Medics Pty Ltd is the international representative for the SmartPlus insulin pen in Australia under the approval of the Therapeutic Goods Administration (TGA) in Australia.
RevenueN/A
Employees50
Market CapN/A
Founded2005
Sydney, Australia
Emperra Gm
Emperra GmbH E-Health Technologies
Healthcare
Company Headquarters: Potsdam, Germany Founded: 2008 Workforce: ~51-100 Company Working: Emperra GmbH E-Health Technologies is a research and development-driven medical technology start-up company. It offers innovative concepts and solutions in the fields of e-health technologies and telediabetology. In its Esysta system, the company is known for combining innovative software with future-oriented hardware such as the first digitally connected insulin pen. The Esysta system is available and reimbursed in Germany. The company’s diabetic care product line is used for tracking, monitoring, and transmission of diagnostic and therapeutic data of diabetic patients such as insulin doses, blood sugar levels, and carbohydrates.
RevenueN/A
Employees100
Market CapN/A
Founded2007
Potsdam, Germany
Companion
Companion Medical
Healthcare
Company Headquarters: California, US Founded: 2013 Workforce: ~51-200 Company Working: Companion Medical is a leader in the development of innovative solutions & advanced technology for the management of diabetes. It is the first company to received US Food and Drug Administration (FDA) approval for InPen, a smart insulin pen used to improve diabetes care. The InPen system is consists of a Bluetooth-enabled pen that is connected to an app that offers dose reminders for patients. The company offers its products in the treatment of Type 1 and Type 2 diabetes. The firm has a strong presence in North America and Europe.
RevenueN/A
Employees200
Market CapN/A
Founded2012
California, US
Ypsomed
Ypsomed
Healthcare
Company Headquarters: Burgdorf, Switzerland Founded: 2003 Workforce: 1,604 Company Working: Ypsomed Holding AG (Ypsomed) develops, manufactures, and sells injection and infusion systems to pharmaceutical and biotechnology companies. The three business segments of the company include – Ypsomed Diabetes Care, Ypsomed Delivery Systems, and others. The company promotes and sells its products, directly to patients or through pharmacies and clinics under the umbrella brand, mylife Diabetes care. The company offers business-to-business (B2B) to pharmaceutical companies under Ypsomed Delivery Systems (YDS). Ypsomed operates in Switzerland, other European countries, North America, and internationally.
Revenue$0.4B
Employees1,604
Market CapN/A
Founded2002
Burgdorf, Switzerland
Novo Nordi
Novo Nordisk A/S
Healthcare
Company Headquarters: Bagsværd, Denmark Founded: 1923 Workforce: ~43,258 Company Working: Novo Nordisk A/S (Novo Nordisk) is a Danish pharmaceutical company that discovers, manufactures, and commercializes pharmaceutical products. The company’s operating segments are diabetes, hemophilia, growth disorders, obesity, and other biopharmaceuticals. The company has research and development centers in China, India, Denmark, the UK, and the US. It has a strong clinical pipeline of drugs for conditions such as Type 1 diabetes, Type 2 diabetes, obesity, atherosclerosis, and hemophilia and growth disorders. The company operates in 79 countries and markets its products in more than 170 countries.
Revenue$16.3B
Employees43,258
Market CapN/A
Founded1922
Bagsværd, Denmark
Eli Lilly
Eli Lilly and Company
Healthcare
Company Headquarter: Indianapolis, Indiana, US Founded: 1876 Workforce: 42,066 Company Working: Eli Lilly and Company is an American global pharmaceutical company. The company also has offices in Puerto Rico and 17 other countries. Its products are sold in approximately 125 countries. The company is listed on the New York Stock Exchange, and its shares had been a component of the S&P 500 Index since 1971. Lilly was the first company to mass-produce penicillin, the Salk polio vaccine, and insulin. Its achievements include being one of the first pharmaceutical companies to produce human insulin using recombinant DNA including Humulin, Humalog, and the first approved biosimilar insulin product in the US, Basaglar. Lilly is also the world's largest manufacturer and distributor of psychiatric medications including Prozac (Fluoxetine), Dolophine (Methadone), Cymbalta (Duloxetine), and Zyprexa (olanzapine). Some of the top competitors of Eli Lilly and Company are Pfizer Inc., GlaxoSmithKline PLC, Biogen, Sanofi, and Johnson and Johnson.
Revenue$21.2B
Employees42,066
Market CapN/A
Founded1875
United States, North America
Page 1 of 18
…
Go to page
Powering the world's best teams.
From next-gen startups to established enterprises.
What our clients say
Trusted by forward-thinking businesses
for data-driven intelligence
Noah Malgeri
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Michael Robert
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Joseph Aguayo
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Bong Lau
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Peter Groot Koerkamp
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Younghwan Choi
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Mark Irwin
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Rob Kooiker
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
Jason Lee
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Akif Moroglu
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Noah Malgeri
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Michael Robert
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Joseph Aguayo
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Bong Lau
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Peter Groot Koerkamp
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Younghwan Choi
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Mark Irwin
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Rob Kooiker
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
Jason Lee
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Akif Moroglu
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Smart Insulin Pens Market
Starting from
$4,950